Searchable abstracts of presentations at key conferences in endocrinology

ea0028mte6 | (1) | SFEBES2012

Prioritising therapy in neuroendocrine tumours

Toumpanakis Christos

Neuroendocrine tumors (NETs) represent a very heterogenous group of neoplasms, comprising approximately 2% of all malignant tumors of gastroenteropancreatic system. Although they are characterized by a relatively slow tumor growth, they have a malignant potential and, in fact, most of them are diagnosed when distant metastases have been developed. NETs, when functioning, are causing symptoms related not only to the tumour mass itself, but also to the specific hormonal peptide ...

ea0072p3 | (1) | UKINETS2020

Circulating biomarkers to predict progression-free survival in patients with neuroendocrine tumours received 177Lu-DOTATATE

Chen Luohai , Gnanasegaran Gopinath , Mandair Dalvinder , Toumpanakis Christos , Caplin Martyn , Navalkisoor Shaunak

Background: 177Lu-DOTATATE is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few circulating biomarkers are available to predict progression-free survival (PFS) of patients received 177Lu-DOTATATE.Materials and methods: Clinicopathological data and data of baseline circulating biomarkers including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), e...

ea0077p214 | Neuroendocrinology and Pituitary | SFEBES2021

Pregnancy and neuroendocrine neoplasms

Ratnayake Gowri M , Armonis Panagiotis , Hayes Aimee R , Mandair Dalvinder , Khoo Bernard , Toumpanakis Christos , Grossman Ashley B , Caplin Martyn E

Background: The incidence of neuroendocrine neoplasms (NENs) in younger populations (<50 years) is increasing and was 1.8 per 100,000 persons in 2011. There is limited data on NENs and pregnancy.Methods: A retrospective analysis was performed on pregnant women with NENs managed in an ENETS Centre of Excellence. The objectives of the study were to describe the tumour characteristics, pregnancy outcomes, treatment and the tumour behaviour intra-pregnan...

ea0052p23 | (1) | UKINETS2017

Above-label doses of lanreotide Autogel for the treatment of advanced neuroendocrine tumours (NETs)

Laskaratos Faidon-Marios , Banks Jamie , Shah Ruchir , Smith Jack , Jacobs Ben , Galanopoulos Michalis , Caplin Martyn , Mandair Dalvinder , Toumpanakis Christos

Introduction: High doses/frequency of somatostatin analogues (SSA) are often used to control refractory functional symptoms and/or tumour progression in patients treated with standard doses of SSAs, but there is limited evidence for the efficacy of this strategy.Methods: Retrospective analysis of 47 NET patients on lanreotide Autogel 120 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change i...

ea0052p24 | (1) | UKINETS2017

Shortened interval of octreotide LAR administration for the treatment of advanced neuroendocrine tumours (NETs)

Laskaratos Faidon-Marios , Shah Ruchir , Banks Jamie , Jacobs Ben , Smith Jack , Galanopoulos Michalis , Mandair Dalvinder , Caplin Martyn , Toumpanakis Christos

Introduction: Escalated doses of octreotide LAR are commonly used to control functional symptoms and/or tumour growth, but there is limited evidence regarding the efficacy of this approach.Methods: Retrospective analysis of 69 NET patients treated with octreotide LAR 30 mg every 3 weeks (as monotherapy). Progression-free survival (PFS) and clinical outcomes were assessed. A 30% change in symptomatology and biomarker levels was considered significant....

ea0052p18 | (1) | UKINETS2017

Circulating Tumour Cells (CTCs) are associated with bone metastases in patients with Neuroendocrine Tumours (NET)

Rizzo Francesca Maria , Childs Alexa , Mandair Dalvinder , Khan Mohid S , Cives Mauro , Ensell Leah , Lowe Helen , Caplin Martyn E , Toumpanakis Christos , Meyer Tim

Background: Bone metastases have been described in up to 15% of patients with NETs and are associated with a worse clinical outcome. Here we investigate the role of CTCs as a marker of bone metastases in a large cohort of patients with gastroenteropancreatic NETs.Methods: To be eligible for the study, patients were required to be ≥ 18 years old, have histologically confirmed midgut or pancreatic NET (pNET) and metastatic disease measurable by RECIS...

ea0052p29 | (1) | UKINETS2017

Endoscopic submucosal dissection (ESD) of gastric and rectal neuroendocrine tumours (NETs)

Murino Alberto , Bailey James , Telese Andrea , Laskaratos Faidon-Marios , Koukias Nikolaos , Vlachou Erasmia , Luong Tu Vinh , Mandair Dalvinder , Caplin Martyn , Toumpanakis Christos , Despott Edward

Background: Gastrointestinal (GI) neuroendocrine tumours (NETs) are potentially malignant lesions originating from the enterochromaffin cells of the GI tract. These neoplasms often produce characteristic hormonal syndromes and can cause debilitating symptoms. Endoscopic submucosal dissection (ESD) is a well-established, complex, endoscopic technique, which allows for full resection of the mucosal and submucosal lesions without the need for open surgery.M...

ea0052p33 | (1) | UKINETS2017

Double-balloon enteroscopy (DBE) is useful and effective for the diagnosis, assessment and management of small bowel neuroendocrine tumours (SBNETs): a case series from a national tertiary referral centre

Telese Andrea , Murino Alberto , Phillips Edward , Laskaratos Faidon , Luong Tu Vinh , Koukias Nikolaos , Mandair Dalvinder , Toumpanakis Christos , Caplin Martyn , Despott Edward

Background: Although small bowel (SB) neuroendocrine tumours (SBNETs) often present as indolent lesions, late diagnosis may result in poor outcomes. Successful management is therefore dependent on early identification. Double-balloon enteroscopy (DBE) enables direct SB mucosal visualisation, sampling and endotherapy. Our aim was to evaluate the role of DBE for early diagnosis and management of SBNETs.Methods: Retrospective review of all SBNETs diagnosed/...

ea0068p10 | Abstracts | UKINETS2019

Type III gastric neuroendocrine neoplasms: moving towards less-extensive resections in selected cases?

Exarchou Klaire , Kameniarz Lukasz , Victor Alexandra , Khan Mohid , Srirajaskanthan Raj , Mandair Dalvinder , Ramage John , Caplin Martyn , Pritchard David Mark , Toumpanakis Christos

Background: Type III gastric neuroendocrine neoplasms (g-NEN) are usually lesions of higher grade and often associated with loco-regional and distant metastases. Guidelines recommend partial or total gastrectomy with local lymph node resection. Data for less-extensive resections are limited.Aim: To assess whether advanced endoscopic excision [Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD)] or localized surgical approach (wed...

ea0060p20 | (1) | UKINETS2018

Chest metastases in advanced small bowel neuroendocrine neoplasms: incidence and outcome

Birk Jasryan , Jacobs Ben , Bailey James , Musaddaq Besma , Stempel Conrad Von , Brown Adam , Furnace Myles , Mandair Dalvinder , Caplin Martyn , Cleverley Joanne , Toumpanakis Christos

Introduction: Liver is the most common site in patients with advanced small bowel neuroendocrine neoplasms (SBNEN) and distant metastases. On the contrary, lung metastases are relatively uncommon, occurring in 5–13.6% of patients. Although hepatic metastases often progress and have implications to the disease outcome, not enough data are available for lung metastases.Aim: Our aim was to assess the incidence of chest (including lung, mediastina/hilar...